Bruker (NASDAQ:BRKR) Price Target Raised to $53.00

Bruker (NASDAQ:BRKR) had its target price upped by TD Cowen from $42.00 to $53.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a hold rating on the medical research company’s stock.

BRKR has been the topic of a number of other research reports. Rothschild Redb raised Bruker to a “strong-buy” rating in a report on Thursday, November 20th. The Goldman Sachs Group started coverage on shares of Bruker in a research note on Tuesday, December 9th. They issued a “sell” rating and a $40.00 price objective on the stock. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. Finally, Guggenheim boosted their target price on Bruker from $45.00 to $53.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Bruker has a consensus rating of “Hold” and a consensus price target of $52.29.

Bruker Stock Performance

Bruker stock opened at $54.46 on Wednesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. Bruker has a 12 month low of $28.53 and a 12 month high of $64.64. The stock’s 50-day moving average is $46.14 and its 200-day moving average is $39.74. The company has a market cap of $8.27 billion, a price-to-earnings ratio of -340.38, a price-to-earnings-growth ratio of 6.80 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter last year, the firm posted $0.60 EPS. The business’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities analysts anticipate that Bruker will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Bruker’s dividend payout ratio (DPR) is -125.00%.

Insider Buying and Selling

In other Bruker news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

Institutional investors have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd acquired a new position in shares of Bruker in the 2nd quarter worth approximately $192,735,000. AQR Capital Management LLC increased its position in shares of Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker during the second quarter worth about $62,032,000. Norges Bank bought a new position in shares of Bruker during the 2nd quarter worth approximately $44,459,000. Finally, UBS Group AG lifted its position in Bruker by 196.4% during the 3rd quarter. UBS Group AG now owns 1,413,919 shares of the medical research company’s stock worth $45,938,000 after buying an additional 936,820 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Key Stories Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker said it acquired the remaining 60% of TOFWERK, taking full ownership to 100% and folding TOFWERK’s ultra-fast TOF mass‑spectrometry tech into Bruker’s applied markets push (air quality, exposomics, food/flavor, atmospheric chemistry). This is a strategic product/market expansion that can drive revenue diversification and higher-margin applied‑markets growth. Bruker Consolidates Ownership of TOFWERK
• Positive Sentiment: Bruker’s BEST division announced roughly $500 million in multi‑year supply agreements with two global radiology customers to supply advanced superconductors for MRI magnets — a material long‑lead, high‑value product that supports recurring revenue and visibility. That large contract flow is the primary near‑term catalyst cited by market reports. Bruker Announces $500 Million in Multi-Year Orders
• Positive Sentiment: TD Cowen raised its price target on BRKR to $53.00, signaling incremental analyst support for the stock’s outlook (note: analyst moves can boost sentiment even if PTs lag recent prices). TD Cowen Boosts Bruker Price Target
• Positive Sentiment: A recent Seeking Alpha piece argues BRKR may be attractively valued ahead of an earnings inflection, reinforcing a bullish narrative among value/growth investors. Bruker: Attractive Valuation Ahead Of An Earnings Inflection
• Neutral Sentiment: Bruker is scheduled to present at the J.P. Morgan Healthcare Conference — a visibility event that can catalyze investor interest but is informational rather than an operational development. Bruker Corporation to Present at the J.P. Morgan Healthcare Conference
• Negative Sentiment: Zacks Research trimmed Q4/FY EPS estimates marginally (Q4 to $0.65, FY2025 to $1.89 and FY2027 to $2.44), reflecting modest near‑term analyst downgrades that could limit upside if guidance/earnings miss. Zacks trims EPS estimates for Bruker

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.